Recent Updates
Recently added Catalysts
INDV Positive Sentiment Score: 70/100

Indivior to Announce Q1 2024 Results and Host Webcast on April 25 th Slough, UK, and Richmond, VA

Key Takeaway: Indivior PLC has announced that it will release its Q1 2024 financial results on April 25, 2024, at 7:00 a.m. London time. Following the results announcement, a live webcast will be hosted by Chief Executive Officer Mark Crossley and other leadership team members at 1:00 p.m. London time to discuss the outcomes. This event underscores Indivior's commitment to developing drugs for substance use disorders and related conditions.

Market Sentiment Analysis

POSITIVE FACTORS

  • Indivior is set to announce its Q1 2024 results, indicating ongoing operations.
  • The company is focused on treating substance use disorders and expanding its product pipeline.
  • A live webcast will engage stakeholders directly, enhancing transparency.

Full Press Release Details

to Announce Q1 2024 Results and Host Webcast on April
Slough, UK, and Richmond, VA, April 8,
2024 - Indivior PLC (LSE/NASDAQ: INDV) today announced
that it will release its Q1 2024 results on April
7:00 a.m. London time (2:00 a.m. U.S. Eastern).
available via the London Stock Exchange's Regulatory News Service
(RNS) and on the "Investors" section of the company's website
Mark Crossley, Chief Executive Officer, and other members of
Indivior's leadership team will host a presentation via live
webcast at 1:00 p.m. London time (8:00 a.m. U.S. Eastern) on April
Access to the Live Webcast Presentation:
The webcast event and materials can be accessed on the "Investors"
section of the company's website at www.indivior.com before
Participants may access the presentation telephonically by
registering with the following link:
(Registrants will have an
option to be called back directly immediately prior to the call or
be provided a call-in # with a unique pin code following their
A replay of the presentation will be available
Indivior is a global pharmaceutical company working to help change
patients' lives by developing medicines to treat substance use
disorders (SUD) and serious mental illnesses. Our vision is that
all patients around the world will have access to evidence-based
treatment for the chronic conditions and co-occurring disorders of
SUD. Indivior is dedicated to transforming SUD from a global human
crisis to a recognized and treated chronic disease. Building on its
global portfolio of OUD treatments, Indivior has a pipeline of
product candidates designed to both expand on its heritage in this
category and potentially address other chronic conditions and
co-occurring disorders of SUD, including alcohol use disorder and
cannabis use disorder. Headquartered in the United States in
Richmond, VA, Indivior employs more than 1,000 individuals globally
and its portfolio of products is available in 37 countries
worldwide. Visit www.indivior.com to learn more. Connect with Indivior on
LinkedIn by visiting www.linkedin.com/
Vice President, Investor Relations
Tel: 804-402-7123 or jason.thompson@indivior.com
Director, Investor Relations
Tel: 804-263-3978 or timothy.owens@indivior.com

Frequently Asked Questions

When will Indivior release its Q1 2024 results?

Indivior will release its Q1 2024 results on April 7 at 7:00 a.m. London time.

How can I access the Indivior webcast presentation?

You can access the webcast on Indivior's Investors section at www.indivior.com.

Who will present during the Indivior webcast?

Mark Crossley, CEO, and other leaders from Indivior's team will present.

Is there a replay available for the Indivior presentation?

Yes, a replay will be available at www.indivior.com after the event.

What is Indivior's mission as a company?

Indivior aims to transform substance use disorders into recognized chronic diseases.

Last updated: Apr 8, 2024